Luigi Naldini, PhD
Affiliations: | San Raffaele-Telethon Institute for Gene Therapy (TIGET) |
Google:
"Luigi Naldini"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Castiello MC, Brandas C, Ferrari S, et al. (2024) Exonic knockout and knockin gene editing in hematopoietic stem and progenitor cells rescues RAG1 immunodeficiency. Science Translational Medicine. 16: eadh8162 |
| Canarutto D, Asperti C, Vavassori V, et al. (2023) Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4 T-cells for the treatment of Hyper IgM1. The Embo Journal. e114188 |
| Kerzel T, Giacca G, Beretta S, et al. (2023) In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell. 41: 1892-1910.e10 |
| Asperti C, Canarutto D, Porcellini S, et al. (2023) Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated and . Molecular Therapy. Methods & Clinical Development. 30: 546-557 |
| Ferrari S, Naldini L. (2023) A step toward stem cell engineering in vivo. Science (New York, N.Y.). 381: 378-379 |
| Canarutto D, Omer Javed A, Pedrazzani G, et al. (2023) Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation. British Medical Bulletin |
| Vavassori V, Ferrari S, Beretta S, et al. (2023) Lipid Nanoparticles Allow Efficient and Harmless Ex Vivo Gene Editing of Human Hematopoietic Cells. Blood |
| Ferrari S, Valeri E, Conti A, et al. (2023) Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 30: 549-570 |
| Omer-Javed A, Pedrazzani G, Albano L, et al. (2022) Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells. Cell. 185: 2248-2264.e21 |
| Milani M, Canepari C, Liu T, et al. (2022) Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nature Communications. 13: 2454 |